Foslevodopa

Summary

Foslevodopa (CHEMBL4594379) is an approved small-molecule antiparkinson drug; indicated across 1 condition including parkinson disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 7
• Chemistry: 277.17 Da · C9H12NO7P

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4594379
Name	Foslevodopa
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	127766
ChEBI	CHEBI:192509
Molecular formula	C9H12NO7P
Molecular weight	277.17
InChIKey	YNDMEEULGSTYJT-LURJTMIESA-N

SMILES: C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)OP(=O)(O)O

IUPAC name: (2S)-2-amino-3-(3-hydroxy-4-phosphonooxyphenyl)propanoic acid

ChEBI definition: An L-tyrosine derivative that is L-dopa in which the hydroxy group at position 4’ is replaced by a phosphonooxy group. It is a water-soluble prodrug of levodopa which is used for the treatment of Parkinson’s disease.

Pharmacological roles (ChEBI): antiparkinson drug, prodrug.

Also known as: ABBV-951, Foslevodopa, FOSLEVODOPA COMPONENT OF ABBV-951, Foslevodopa component of vyalev, Levodopa-4’-monophosphate, FOSLEVODOPA

Patent coverage: 47 distinct patent families (117 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 109 (93%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
Parkinson disease	3	MONDO:0005180	MONDO:0005180

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE3	4
PHASE1	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04750226	PHASE3	ACTIVE_NOT_RECRUITING	Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson’s Disease
NCT03781167	PHASE3	COMPLETED	A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson’s Disease (PD)
NCT04379050	PHASE3	COMPLETED	Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson’s Disease
NCT04380142	PHASE3	COMPLETED	Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson’s Disease
NCT03033498	PHASE1	COMPLETED	A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson’s Disease
NCT03374917	PHASE1	COMPLETED	A Study in Subjects With Parkinson’s Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient Environment
NCT05094050	PHASE1	COMPLETED	Study to Assess How ABBV-951 is Absorbed When Administered at Different Subcutaneous Sites of Adult Participants With Parkinson’s Disease

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).